Pepmixes for Multiviral CTL Generation

Baylor College of Medicine filed patent application US20260092256A1 for methods of generating CTLs with broad specificity against multiple viruses. The invention involves exposing peptide mixtures from different viral antigens to the same plurality of peripheral blood mononuclear cells (PBMCs), with cell expansion using IL4 and IL7 cytokines. The application covers pepmixes for at least two viruses and various CPC classifications including C12N 5/0638, A61K 39/12, and related pharmaceutical compositions.

This is a published patent application representing a novel immunotherapy method rather than a regulatory compliance requirement. Organizations developing cellular therapies, antiviral immunotherapies, or related biologics should review the published claims for potential freedom-to-operate or licensing considerations. Patent prosecution typically takes 2-3 years before issuance.